Eli Lilly
NYSE: LLY · Health Care · Pharmaceuticals · INDIANAPOLIS, IN
Pharmaceutical company whose GLP-1 incretin medicines (Mounjaro, Zepbound) for diabetes and obesity drive growth, alongside oncology, immunology and neuroscience drugs.
Annual results
Click any number to open the SEC filing it came from.
| Line | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $28.3B | $28.5B | $34.1B | $45.0B | $65.2B |
| Net income | $5.6B | $6.2B | $5.2B | $10.6B | $20.6B |
| EPS — diluted | $6.12 per share | $6.90 per share | $5.80 per share | $11.71 per share | $22.95 per share |
| Cash from operations | $7.4B | $7.6B | $4.2B | $8.8B | $16.8B |
| Free cash flow | $6.1B | $5.7B | $792.0M | $3.8B | $9.0B |
| Total assets | $48.8B | $49.5B | $64.0B | $78.7B | $112.5B |
Recent filings
Members see much more
The full LLY file, with an AI analyst on it.
- Quarterly statements, segments and IR data
- Valuation, earnings and insider activity
- A research assistant that cites the filing sentence